Rchr
J-GLOBAL ID：200901002788747897   Update date: Sep. 25, 2022

Itamochi Hiroaki

イタモチ ヒロアキ | Itamochi Hiroaki
Affiliation and department：
Iwate Medical University Hospital, Obstetrics and Gynecology

About Iwate Medical University Hospital, Obstetrics and Gynecology


Job title： Professor
Research field  (1)： Obstetrics and gynecology
Research keywords  (2)： Obstetrics and Gynecology ,  産婦人科学
Research theme for competitive and other funds  (2)：
  • 婦人科癌に対する化学療法
  • Chemotherapy for gynecologic malignancy
Papers (228)：
  • Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, et al. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. 24. 16. 3928-3940
  • Shoji T, Komiyama S, Kigawa J, Tanabe H, Kato K, Itamochi H, Fujiwara H, Kamiura S, Hamano T, Sugiyama T, et al. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizuma. BMC cancer. 2018. 18. 1. 771
  • Daisuke Fukagawa, Tamotsu Sugai, Mitsumasa Osakabe, Yasuko Suga, Takayuki Nagasawa, Hiroaki Itamochi, Toru Sugiyama. Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers. Oncotarget. 2018. 9. 44. 27514-27524
  • Katrien Berns, Joseph J. Caumanns, E. Marielle Hijmans, Annemiek M. C. Gennissen, Tesa M. Severson, Bastiaan Evers, G. Bea A. Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L. Beijersbergen, et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene. 2018. 1-15
  • Ryo Tamura, Kosuke Yoshihara, Tetsuya Saito, Ryosuke Ishimura, Juan Emmanuel Martínez-Ledesma, Hu Xin, Tatsuya Ishiguro, Yutaro Mori, Kaoru Yamawaki, Kazuaki Suda, et al. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 2018. 7. 1. 4-4
ｍore...
MISC (2)：
  • Itamochi H, Kigawa J. [Molecular targeted therapies for epithelial ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine. 2012. 70 Suppl 4. 622-627
  • 佐藤 慎也, 島田 宗昭, 板持 広明. Current status of target therapy for gynecologic cancer. 産婦人科治療. 2011. 103. 2. 215-219
Books (16)：
  • Cervical Cancer - Screening, Treatment and Prevention
    2018
  • Precision Medicine in Gynecology and Obstetrics, Comprehensive Gynecology and Obstetrics
    2017
  • Advances in DNA Repair
    2015
  • II. 腫瘍 C. 卵巣がん 9. 推奨される分子標的薬は?
    中外医学社 2013
  • Ovarian Cancer - A Clinical and Translational Update
    2013
ｍore...
Professional career (1)：
  • (BLANK)
Committee career (4)：
  • - 現在 日本癌治療学会 代議員
  • - 現在 日本ヒト細胞学会 理事
  • - 現在 日本婦人科腫瘍学会 理事
  • - 現在 日本臨床細胞学会 理事
Awards (3)：
  • 2012/03 - 鳥取大学 科学研究業績表彰(日ノ丸賞)
  • 2011/09 - 中国四国産科婦人科学会 学会賞(八木賞)
  • 2009/03 - 下田光造記念賞
Association Membership(s) (11)：
International Gynecologic Cancer Society ,  American Society of Clinical Oncology ,  American Association for Cancer Research ,  日本婦人科腫瘍学会 ,  日本臨床細胞学会 ,  日本癌治療学会 ,  日本癌学会 ,  日本産科婦人科学会 ,  International Gynecologic Cancer Society ,  American Society of Clinical Oncology ,  American Association for Cancer Research
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM